• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 22, 2011

View Archived Issues

Exelixis Hands Merck PI3K-Delta Program in $251M Deal

True to its word, Exelixis Inc. started to prune its pipeline this week, handing Merck & Co. Inc. an exclusive worldwide license to its phosphoinositide-3 kinase (PI3K)-delta research and development program, including XL499 – the company's most advanced preclinical PI3K-delta inhibitor – and related compounds. Read More

Takeda Pharmaceutical to Acquire Intellikine in $320M Deal

Takeda Pharmaceutical Co. Ltd. agreed to acquire Intellikine Inc., of La Jolla, Calif., for $190 million up front, with $120 million in potential clinical milestone payments. Intellikine's assets include small molecule kinase inhibitors of the phoshoinositide-3 kinase (PI3K 1) and mammalian target of rapamycin (mTOR2) pathways with ongoing Phase I trials in solid tumors and hematologic malignancies. Read More

Unbiased Interaction Screen Uncovers HIV Helpers Galore

Back-to-back studies published in Nature this week reported a comprehensive catalog of proteins that HIV interacts with in human cells, then followed up on one of those interactions in greater detail. The studies provide new insights into how HIV uses its host – and also a wealth of possible new targets to treat HIV infections. Read More

Ranbaxy Pays Price to Restore Full Access to U.S. Market

WASHINGTON – A consent decree with the FDA and a potential $500 million settlement with the Department of Justice (DOJ) are the price Ranbaxy Laboratories Ltd. is paying to once again have complete access to the U.S. market. Read More

Holiday Notice

BioWorld's offices will be closed Friday, Dec. 23, and Monday, Dec. 26, in observance of the Christmas Day holiday. No issues will be published those days. Read More

Other News To Note

• Lycera Corp., of Ann Arbor, Mich., said it reached the first milestone under its research collaboration with Merck & Co. Inc., of Whitehouse Station, N.J., triggering an undisclosed milestone payment. The collaboration is focused on developing drug candidates that target T-helper 17 (Th17) cells, key mediators of inflammation, to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis. (See BioWorld Today, March 4, 2011.) Read More

Stock Movers

Read More

Financings Roundup

• Ariad Pharmaceuticals Inc., of Cambridge, Mass., completed its previously announced public offering of 24.7 million common shares, including overallotment, priced at $10.42 each, for gross proceeds of $257 million. Net proceeds of $243 million will support pivotal trial follow-up and approval filings for leukemia drug ponatinib. (See BioWorld Today, Dec. 16, 2011.) Read More

Clinic Roundup

• Celldex Therapeutics Inc., of Needham, Mass., completed accrual for its Phase IIb (EMERGE) trial of CDX-011 (glembatamumab vedotin) for metastatic breast cancer. The drug targets glycoprotein NMB (GPNMB). The randomized, controlled trial enrolled heavily pre-treated breast cancer patients unlikely to benefit from any approved therapies and whose tumors express GPNMB. Endpoints include response rate and progression-free survival. The trial is being carried out at 20 sites within the U.S. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe